ErVaccine Technologies announces the publication of a new paper in American Journal of Hematology
June 29, 2022

ErVaccine Technologies, a preclinical-stage biotechnology company, announces the publication of a new paper in American Journal of Hematology‘HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy showing that HERVs represent an important source of genetic information that can help enhancing disease stratification or biomarker identification and an important reservoir of alternative tumor-specific T cell epitopes relevant for cancer immunotherapy strategies.

This approach founded by ErVaccine and exemplified here in acute myeloid leukemia, could easily be extended to any disease to provide a better risk-stratification, establish relevant predictive signatures for therapeutic responses or identify original therapeutic targets.

Click here to read the article

About ErVimmune

Medical research and development, in particular the development of new families of tumour antigens.

Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.

Useful links

> Publications & abstracts

> Recent news

> Legal notice


> Home

> About us

> Sciences

> Investors

> Join us

> Contact



+33 6 67 67 44 97

© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go